May 2022
-
Alternative Dosing Strategies for Immune Checkpoint Inhibitors
Combining fixed- and weight-based dosing approaches may reduce costs without compromising efficacy.
-
US FDA’s Review of Single-Country ‘Me Too’ Drugs: A Clinical Trialist Perspective
With no direct comparison to the standard of care and limited resources to review applications, researchers say they support the agency’s decision not to approve sintilimab.
-
Panel Explores Emerging Treatments and Sequencing Strategies for Patients with Advanced NSCLCs Driven by Rare Oncogenes
During the 2022 European Lung Cancer Congress, experts reviewed evidence on drugs targeting MET exon 14 skipping mutations and RET, HER2, and BRAF alterations.
-
Evidence Supports Adding Biological, Pathological, and Molecular Assessments to the TNM Lung Cancer Staging System
A presentation at the 2022 European Lung Cancer Congress convinced attendees that the current system for staging lung cancer needs refinement.
-
Renowned Researcher Fred Hirsch Delivers 2022 Heine H. Hansen Award Lecture
The honor of giving the opening keynote address during ELCC recognizes Dr. Hirsch’s significant contributions to international research and education.
-
In Brief for May 25, 2022
5th edition of patient education book released; US FDA moves to prohibit tobacco flavoring.
-
Financial Toxicity of Lung Cancer in the Netherlands
Even when treatment costs are covered, the majority of lung cancer patients experience increased expenses and/or reduced income following their diagnoses.
-
As Treatment Options in Lung Cancer Have Expanded, so Have Costs
A real-world look at diagnostic-therapeutic pathways explores how they may help provide optimal, innovative care without ballooning costs.
-
Small, High PLCG2-Expressing Intratumoral Cells May Drive Metastasis
In the search to understand the mechanisms of metastasis, researchers have expanded the spectrum of SCLC clinical specimens amenable for single-cell resolution analysis.
-
COAST Data Support Further Research of Immunotherapy Combinations
Trial is the first to show improved efficacy and a manageable safety profile after cCRT in unresectable locally advanced stage III NSCLC regardless of PD-L1 status.
View ILCN Archives
Provider Resources